Hong Kong Stock Movement
CLOUDBREAK-B rose 10.25%. Based on recent key news:
<ol>
<li>
On December 8, CLOUDBREAK-B announced that its subsidiary Cloudbreak USA will hold a Phase 2 clinical trial post-meeting with the U.S. Food and Drug Administration on December 10, involving the candidate drug CBT-004. This meeting is an important milestone in the R&amp;D process, driving the stock price up. Source: Zhitong Finance
</li>
<li>
On December 8, CLOUDBREAK-B's announcement showed that CBT-004 demonstrated good safety and efficacy in clinical trials, achieving its primary endpoint, further enhancing market confidence. Source: Zhitong Finance
</li>
<li>
On December 8, Economic Information Daily reported that CLOUDBREAK-B's clinical trial post-meeting will discuss the development of Phase 3 clinical trials and new drug application requirements, indicating future development potential. Source: Economic Information Daily. The progress of ophthalmic drug R&amp;D drives the stock price up.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Innovent Biologics fell 6.79%. Based on recent key news:
<ol>
<li>
On December 8, Innovent Biologics announced that seven of its innovative products were successfully included in the new national medical insurance catalog, covering fields such as oncology and cardiovascular diseases, improving patient access to medications. However, the stock price still fell, reflecting market concerns about short-term performance. Source: Zhitong Finance
</li>
<li>
On December 5, Innovent Biologics reached a global strategic cooperation with Takeda Pharmaceutical, issuing 6.9138 million shares, with net proceeds of approximately HKD 777 million. Despite the positive outlook for cooperation, the stock price failed to break through previous highs. Source: Zhitong Finance
</li>
<li>
On December 8, there were multiple large transactions in front of Innovent Biologics, involving approximately 13.0734 million shares at an average price of HKD 92 per share, indicating the market's cautious attitude towards its short-term trend. Source: Economic Information Daily. The pharmaceutical sector recently lacks a clear main line, and enthusiasm for innovative drug investments may be boosted.
</li>
</ol>
Rongchang Biologics fell 10.36%. Based on recent key news:
<ol>
<li>
On December 8, the success rate of national medical insurance negotiations reached a historical high, and the commercial insurance catalog is expected to become an important increment, with policies encouraging the development of innovative drugs. Rongchang Biologics, as an innovative drug company, received attention, but the market's reaction to policy support was below expectations, leading to a decline in stock price. Source: Zhitong Finance
</li>
<li>
On December 5, CMB International pointed out that the proportion of domestic capital holding pharmaceutical stocks through the Hong Kong Stock Connect has decreased, and foreign capital holdings have also retreated. Although the direction of innovative drug layout remains unchanged, domestic capital tends to take profits, affecting Rongchang Biologics' stock price. Source: Jinwu Finance
</li>
<li>
On December 5, there are ample catalysts within the industry, including the announcement of medical insurance negotiation results and potential interest rate cuts by the Federal Reserve, which may stabilize investment sentiment in the sector, but in the short term, Rongchang Biologics' stock price remains under pressure. Source: Jinwu Finance. Policy support for the innovative drug industry still carries risks.
</li>
</ol>
Kangfang Biologics rose 0.08%. Based on recent key news:
<ol>
<li>On December 7, Kangfang Biologics announced that its five newly launched drugs were successfully included in the 2025 version of the national medical insurance drug catalog. This move increases the market accessibility and sales potential of the drugs, driving the stock price up
Source: Zhitong Finance</li>
</ol>
On December 8, Economic Information Daily reported that five new drugs from CanSino Biologics have been included in the latest national medical insurance catalog, further confirming the company's success in medical insurance negotiations and enhancing investor confidence. Source: Economic Information Daily
On December 7, CanSino Biologics announced that the expansion of its new drug indications and successful contract renewals have increased market expectations for the company's future growth. Source: Huigang Communications The biopharmaceutical industry has recently seen favorable policies, with significant capital inflows.
Stocks ranked among the top in industry market capitalization
BeiGene fell 2.47%. Based on recent key news:
On December 8, the National Healthcare Security Administration released a new version of the drug catalog, with two of BeiGene's drugs entering the commercial insurance innovative drug catalog, attracting market attention. The new catalog will be implemented on January 1, 2026, and is expected to expand the market space for innovative drugs. Source: Zhitong Finance
On December 8, a research report from CMB International pointed out that the pharmaceutical industry is experiencing a critical turning point, with continuous attention on innovative drug layouts. BeiGene is recommended as a target with rich short-term catalysts, as its valuation does not reflect the value of its core blockbuster products. Source: Zhitong Finance
On December 8, a report from Daiwa Securities analysts stated that BeiGene is achieving revenue growth through new products, and global sales are expected to continue to grow in the coming years. Analysts give a buy rating with a target price of HKD 252. Source: Zhitong Finance The innovative drug market is expanding, with clear policy support

02592

CLOUDBREAK-B rose 10.25%; Innovent Biologics fell 6.79%, with a transaction volume of HKD 4.198 billion; Rongchang Biologics fell 10.36%, with a transaction volume of HKD 996 million; CanSino Biologics rose 0.08%, with a transaction volume of HKD 691 million; BeiGene fell 2.47%, with a market value of HKD 297.5 billion

Hong Kong Stock Movement: CLOUDBREAK-B rises 10.25%, clinical trial progress and FDA meeting boost market confidence